Therapeutics News and Research

RSS

Researchers use computational analysis to identify new Achilles heel for drug-resistant breast cancer

Researchers have used computational analysis to identify a new Achilles heel for the treatment of drug-resistant breast cancer. The results, which are published in Molecular Systems Biology, reveal that the disruption of glucose metabolism is an effective therapeutic strategy for the treatment of tumours that have acquired resistance to front-line cancer drugs such as Lapatinib.

31 Jul 2012

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

31 Jul 2012

Two new targets could enhance the body's defenses against West Nile and hepatitis C

Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection warning system inside living cells.

31 Jul 2012

Gluconeogenesis severely compromised in HCC by IL6-Stat3-mediated activation of miR-23a

As liver cancer develops, tumor cells lose the ability to produce and release glucose into the bloodstream, a key function of healthy liver cells for maintaining needed blood-sugar levels.

31 Jul 2012

Grant provides funding for i.v.STATION Robot at Mangiagalli Clinic

Health Robotics today announced that i.v.STATION and Mangiagalli's Clinic won a national grant from the Vodafone Foundation, as selected by Vodafone customers' votes from a group of potential projects, all of which were focused on children's welfare.

30 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012.

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

New computational method to help organize scientific data

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help organize scientific data, making it easier for scientists to identify and prioritize genes, drug targets, and connections between drugs. By mining large datasets more simply and efficiently, researchers will be able to better understand gene-gene, protein-protein, and drug/side-effect interactions.

27 Jul 2012

Vaccine complex delivered safely by piggybacking onto 3D DNA nanostructures

In a quest to make safer and more effective vaccines, scientists at the Biodesign Institute- at Arizona State University have turned to a promising field called DNA nanotechnology to make an entirely new class of synthetic vaccines.

27 Jul 2012

LPL deficiency treatment poised to be first gene therapy in Europe

For the first time, the European Medicines Agency has recommended gene therapy for approval in Europe.

26 Jul 2012

Hyperion prices initial public offering of 5,000,000 shares of common stock

Hyperion Therapeutics, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.

26 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

Guided Therapeutics seeks premarket approval from FDA for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc. today announced that it met with the Food and Drug Administration (FDA) on July 20, 2012. The company believes the meeting was very positive and plans to work with FDA to finalize the path forward to gain premarket approval (PMA) for the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Karyopharm commences two KPT-330 phase 1 studies in cancers

Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330.

25 Jul 2012

Alexion second quarter net product sales increase to $274.7 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2012.

25 Jul 2012

MASL protein from plant's seeds may halt spread of melanoma

An international team of scientists led by Gary Goldberg, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM), has found that a protein from the seeds of a plant used for centuries in traditional medicines may be able to halt the spread of melanoma, a lethal form of skin cancer.

25 Jul 2012

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Fewer than 100 researchers nationwide are chosen each year to receive the Presidential Early Career Award for Scientists and Engineers (PECASE), and this year Dr. Nihal Altan-Bonnet is one of the 96 to receive this honor.

25 Jul 2012

Elan second quarter total revenue increases 6% to $288.0 million

Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

25 Jul 2012

Therapeutics News and Research

Researchers use computational analysis to identify new Achilles heel for drug-resistant breast cancer

Advanced understanding of neurodegenerative diseases achieved by Trophos

Two new targets could enhance the body's defenses against West Nile and hepatitis C

Gluconeogenesis severely compromised in HCC by IL6-Stat3-mediated activation of miR-23a

Grant provides funding for i.v.STATION Robot at Mangiagalli Clinic

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Scientists discover new way to combat post-surgical scarring for glaucoma patients

New computational method to help organize scientific data

Vaccine complex delivered safely by piggybacking onto 3D DNA nanostructures

LPL deficiency treatment poised to be first gene therapy in Europe

Hyperion prices initial public offering of 5,000,000 shares of common stock

Insomnia: an interview with Dr Darryle Schoepp

Guided Therapeutics seeks premarket approval from FDA for LuViva Advanced Cervical Scan

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Karyopharm commences two KPT-330 phase 1 studies in cancers

Alexion second quarter net product sales increase to $274.7 million

MASL protein from plant's seeds may halt spread of melanoma

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Elan second quarter total revenue increases 6% to $288.0 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News